Ebos Group Ltd (EBO)
Australian Securities Exchange · Australia · prices in AUD · close of 19 Oct 2026
Key indicators
| Last close | AUD 16.24 |
|---|---|
| 52-week range | 14.87 – 24.83 |
| Return, 1 month / 3 months | +2.0% / −10.1% |
| Return, 1 year / 3 years | −31.5% / −43.7% |
| Trend | Below its 200-day average |
| RSI (14) | 54 |
| Volatility (1 year) | 27.4% |
| Worst drawdown (1 year) | -38.3% |
| Average daily value traded | 2.02M AUD |
| Dividend yield | 5.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ebos Group is a healthcare and animal care products company based in New Zealand. It distributes prescription medicines, medical devices, over-the-counter healthcare products and consumer goods to pharmacies, hospitals and other healthcare providers, and it supplies veterinary medicines, pet food and animal care products to veterinary clinics and pet retailers. The company also provides logistics, wholesale distribution and related support services to manufacturers and retailers across its markets in New Zealand and Australia.
Ebos Group Ltd trades under the code EBO on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ebos Group Ltd (EBO) trades on the Australian Securities Exchange in Australia. It last closed at AUD 16.24 on 19 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 561 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 31.5% and over the last three months it fell 10.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 57 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -8.8% | ||
| From 52-week high | -33.0% | ||
| Momentum | 47 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -10.1% | ||
| 6-month return | -4.2% | ||
| 12-month return, skipping the last month | -32.8% | ||
| Stability (higher is calmer) | 81 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 27.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -38.3% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 2.02M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | 54 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.3% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +1.8% |
|---|---|
| 1 month | +2.0% |
| 3 months | −10.1% |
| 6 months | −4.2% |
| 1 year | −31.5% |
| 3 years | −43.7% |
| 5 years | −44.2% |
Signals
| 50-day / 200-day average | 16.61 / 17.81 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.40 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 Aug 2026 | AUD 0.4395 |
| 5 Mar 2026 | AUD 0.4201 |
| 4 Sep 2025 | AUD 0.4919 |
| 27 Feb 2025 | AUD 0.4589 |
| 29 Aug 2024 | AUD 0.5043 |
| 29 Feb 2024 | AUD 0.4683 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.